Ross Osborn
Stock Analyst at Cantor Fitzgerald
(1.98)
# 3,151
Out of 5,015 analysts
117
Total ratings
28.7%
Success rate
-1.61%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORGO Organogenesis Holdings | Maintains: Overweight | $7 → $9 | $3.96 | +127.27% | 4 | Aug 8, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Neutral | $92 → $95 | $86.05 | +10.40% | 2 | Aug 6, 2025 | |
| CVRX CVRx, Inc. | Reiterates: Overweight | $11 | $8.95 | +22.91% | 3 | Aug 5, 2025 | |
| SIBN SI-BONE | Reiterates: Overweight | $25 | $14.78 | +69.15% | 10 | Aug 5, 2025 | |
| MDXG MiMedx Group | Maintains: Overweight | $11 → $12 | $6.55 | +83.21% | 5 | Jul 31, 2025 | |
| BVS Bioventus | Initiates: Overweight | $12 | $6.51 | +84.33% | 1 | Jul 7, 2025 | |
| XGN Exagen | Maintains: Overweight | $8 → $7 | $10.95 | -36.07% | 6 | May 15, 2025 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $2 | $1.15 | +73.91% | 6 | May 15, 2025 | |
| NPCE NeuroPace | Reiterates: Overweight | $17 | $10.28 | +65.37% | 7 | May 14, 2025 | |
| NNOX Nano-X Imaging | Maintains: Overweight | $12 → $9 | $3.90 | +130.77% | 11 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $46 | $29.86 | +54.05% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $0.89 | +798.88% | 10 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $15.99 | +50.09% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.60 | +150.00% | 4 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $9 | $13.89 | -35.21% | 7 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $4.61 | +95.23% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $5.14 | +308.56% | 10 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $6.38 | +150.78% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $1.42 | +146.48% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.46 | +438.68% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.60 | - | 7 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8.61 | $0.49 | +1,662.18% | 2 | Aug 18, 2023 |
Organogenesis Holdings
Aug 8, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $3.96
Upside: +127.27%
LeMaitre Vascular
Aug 6, 2025
Maintains: Neutral
Price Target: $92 → $95
Current: $86.05
Upside: +10.40%
CVRx, Inc.
Aug 5, 2025
Reiterates: Overweight
Price Target: $11
Current: $8.95
Upside: +22.91%
SI-BONE
Aug 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $14.78
Upside: +69.15%
MiMedx Group
Jul 31, 2025
Maintains: Overweight
Price Target: $11 → $12
Current: $6.55
Upside: +83.21%
Bioventus
Jul 7, 2025
Initiates: Overweight
Price Target: $12
Current: $6.51
Upside: +84.33%
Exagen
May 15, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $10.95
Upside: -36.07%
Lucid Diagnostics
May 15, 2025
Reiterates: Overweight
Price Target: $2
Current: $1.15
Upside: +73.91%
NeuroPace
May 14, 2025
Reiterates: Overweight
Price Target: $17
Current: $10.28
Upside: +65.37%
Nano-X Imaging
Apr 1, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $3.90
Upside: +130.77%
Mar 26, 2025
Reiterates: Overweight
Price Target: $46
Current: $29.86
Upside: +54.05%
Mar 7, 2025
Reiterates: Overweight
Price Target: $8
Current: $0.89
Upside: +798.88%
Mar 5, 2025
Reiterates: Overweight
Price Target: $24
Current: $15.99
Upside: +50.09%
Feb 21, 2025
Reiterates: Overweight
Price Target: $4
Current: $1.60
Upside: +150.00%
Jan 16, 2025
Reiterates: Overweight
Price Target: $9
Current: $13.89
Upside: -35.21%
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $4.61
Upside: +95.23%
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $5.14
Upside: +308.56%
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $6.38
Upside: +150.78%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $1.42
Upside: +146.48%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.46
Upside: +438.68%
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $1.60
Upside: -
Aug 18, 2023
Reiterates: Neutral
Price Target: $8.61
Current: $0.49
Upside: +1,662.18%